Efficacy News and Research

RSS

Lux Biosciences announces results of its LX214 human safety study for dry eye syndrome

Lux Biosciences, Inc. a privately held biotechnology company focused on the treatment of ophthalmic diseases, today announced results from a Phase 1 human safety and an open-label pilot efficacy study of the company’s potential best-in-class therapy for dry eye, LX214 (topical mixed nanomicellar formulation of voclosporin).

24 Sep 2009

Advanced Biohealing announces growth strategy to expand its product line

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced a strategic growth plan designed to continue the transformation of this former start-up into the leading international regenerative medicine company.

24 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Four percent annual growth for chronic pain drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the chronic pain drug market will experience modest four percent annual growth from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Although the market will increase over the next decade, generic erosion will constrain sales of key branded agents such as Johnson & Johnson's Topamax (topiramate) and Pfizer's Celebrex (celecoxib).

23 Sep 2009

New Fluorescence Molecular Tomography imaging systems from VisEn Medical

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the launch and availability of a new Fluorescence Molecular Tomography (FMT) imaging system -- the FMT 1500, and an advanced version of its FMT 2500, the FMT 2500 LX.

23 Sep 2009

Stay Fresh textiles technology from Quick-Med

Quick-Med Technologies, Inc. (OTCBB:QMDT) announced today the development of a proprietary Stay Fresh™ technology and that the Company is seeking partners to commercialize this revolutionary new technology in key segments of the textile market.

23 Sep 2009

Alimera Sciences starts pilot study of Iluvien intravitreal insert

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.

23 Sep 2009

Bioelectronics files for pre-marketing clearance for its ActiPatch® Therapy products

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, announced that it filed today with the U.S. Government's Food and Drug Administration for 510(K) pre-marketing clearance for its ActiPatch® Therapy products.

23 Sep 2009

New TAXUS Liberté Stent demonstrates superior results for treating long lesions

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX), has released comprehensive data from the TAXUS ATLAS clinical program, a series of global, prospective, single-arm trials evaluating the TAXUS(R) Liberté(R) Paclitaxel-Eluting Stent System in a variety of lesions and patient groups. Three-year results from the TAXUS ATLAS Small Vessel and Long Lesion Trials continue to show significant advantages for the newer TAXUS Liberté Stent when compared to the first-generation TAXUS(R) Express(R) Stent.

23 Sep 2009

Phase 1 extension study results of Plexxikon's PLX4032 in metastatic melanoma patients encouraging

Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study. PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors.

23 Sep 2009

Culligan and Good Housekeeping Seal celebrate 100th anniversary

In celebration of the 100th birthday of the Good Housekeeping Seal, the magazine’s famous emblem of quality and a limited two-year warranty, the magazine has created an interactive, traveling exhibit that recreates the Good Housekeeping Research Institute, where all product evaluations are conducted.

23 Sep 2009

Medifacts awarded a $1.9M contract to provide cardiac safety services

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiac diagnostic services, today announced the award of a $1.9 million contract with a Global pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

Medtronic's transcatheter valves to be presented at TCT 2009

With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc., announced today that more presentations than ever before – at least 25 – on the company’s portfolio of unique transcatheter valves will be presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009, the world’s premier annual meeting for interventional cardiologists.

23 Sep 2009

Results of OASIS clinical trial reported by Cardiovascular Systems

Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360® PAD System, a minimally invasive catheter system that removes hardened plaque to restore blood flow in arteries.

23 Sep 2009

Update from Advanced Cell on pre-clinical activities for its RPE cell program

Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) provided an update on pre-clinical activities in preparation of its first IND filing with the Food and Drug Administration for its retinal pigment epithelium (RPE) cell program for the treatment of various eye diseases.

23 Sep 2009

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Transoma Medical, Inc., manufacturer of Sleuth AT™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and implant in the COMPLIANCE trial, a long-term study to compare external event recorders with implantable monitors in patients who have been prescribed catheter ablation therapy for atrial fibrillation (AF) at risk of post-procedure AF recurrence.

23 Sep 2009

Patient recruitment completed for crucial glioblastoma study

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy.

23 Sep 2009

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

22 Sep 2009

Millions of H1N1 healthcare consent forms - how to manage them?

As health officials prepare to roll out millions of H1N1 swine flu vaccines this fall, many are contemplating whether to get the shot or risk coming down with the illness. Yet for officials at the state and local level, the question isn’t whether to get the shot, but what to do with the millions of pages of healthcare forms that will begin piling up once the shot becomes available later this year.

22 Sep 2009